SIV vaccine

Drug Profile

SIV vaccine

Alternative Names: SIVdelta3

Latest Information Update: 16 Oct 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Endocon; Institut Pasteur
  • Developer Chiron Corporation; Endocon; Harvard Medical School; National Institutes of Health (USA); New England Regional Primate Center; Nonindustrial source; TSI Mason Laboratories; University of California, Davis
  • Class AIDS vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued HIV infections

Most Recent Events

  • 16 Oct 2005 Discontinued - Preclinical for HIV infections treatment in USA (unspecified route)
  • 02 Jun 1999 A study has been added to the Viral Infections pharmacodynamics section
  • 22 Apr 1997 An in vitro study has been added to the Viral Infections pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top